Is Bivalirudin Legit? Evidence Grade and Plain-English Verdict
Bivalirudin is rated Level A. The short verdict: Bivalirudin (Angiomax) is FDA-approved as an anticoagulant for PCI with Phase 3 data from the HORIZONS-AMI and ACUITY trials showing comparable efficacy to heparin plus GP IIb/IIIa inhibitors with significantly reduced bleeding risk. Its direct thrombin inhibition with predictable pharmacokinetics makes it a preferred anticoagulant in specific interventional cardiology settings.
Direct Answer
Bivalirudin (Angiomax) is FDA-approved as an anticoagulant for PCI with Phase 3 data from the HORIZONS-AMI and ACUITY trials showing comparable efficacy to heparin plus GP IIb/IIIa inhibitors with significantly reduced bleeding risk. Its direct thrombin inhibition with predictable pharmacokinetics makes it a preferred anticoagulant in specific interventional cardiology settings.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Healing & Recovery
- Evidence context
- PCI anticoagulation, direct thrombin inhibitor pharmacology, reduced-bleeding anticoagulation research
Why the Claim Is Strong or Weak
Bivalirudin is a synthetic 20-amino acid peptide that acts as a direct thrombin inhibitor. It is FDA-approved as an anticoagulant for patients undergoing percutaneous coronary intervention.
Reviewed August 27, 2026. A database-wide PubMed candidate sweep and regulatory-status audit were completed. Alias-only and unrelated search matches were excluded; no manually verified update from this review changed the page's evidence grade or bottom-line verdict.
Top Evidence Signals
- PCI Anticoagulation: Level A, includes human evidence - Multiple large RCTs demonstrate effective anticoagulation during PCI with reduced bleeding compared to heparin plus GP IIb/IIIa inhibitors.
- Reduced Major Bleeding: Level A, includes human evidence - HORIZONS-AMI and other trials consistently show significant reduction in major bleeding events compared to heparin-based regimens.
- Acute Stent Thrombosis: Level A, includes human evidence - Slightly increased risk of acute stent thrombosis within 24 hours compared to heparin, likely due to rapid offset. Mitigated by post-PCI infusion protocols.
Where Claims Usually Overreach
- Renal dose adjustment required - predominantly cleared renally
- Increased stent thrombosis risk if infusion stopped abruptly
- No specific reversal agent available
- Use caution with concomitant antiplatelet agents
Primary Sources
- Bivalirudin during primary PCI in acute myocardial infarction (HORIZONS-AMI). N Engl J Med, 2008.
- Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI (EUROMAX). N Engl J Med, 2013.
- Bivalirudin in acute coronary syndromes and percutaneous coronary intervention: a meta-analysis. Eur Heart J, 2015.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | PCI Anticoagulation (Level A), Reduced Major Bleeding (Level A), and Acute Stent Thrombosis (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-08-27 |
Quick Answers
Is Bivalirudin legit?
Bivalirudin is rated Level A. The short verdict: Bivalirudin (Angiomax) is FDA-approved as an anticoagulant for PCI with Phase 3 data from the HORIZONS-AMI and ACUITY trials showing comparable efficacy to heparin plus GP IIb/IIIa inhibitors with significantly reduced bleeding risk. Its direct thrombin inhibition with predictable pharmacokinetics makes it a preferred anticoagulant in specific interventional cardiology settings.
What is the evidence level for Bivalirudin?
Bivalirudin is rated Level A. Its current research status is FDA Approved.
What is Bivalirudin best known for?
PCI anticoagulation, direct thrombin inhibitor pharmacology, reduced-bleeding anticoagulation research.
Where can I read the full Bivalirudin evidence review?
The full evidence review is available at https://examinepeptides.com/library/bivalirudin.
Related Guides
How to Cite This Page
ExaminePeptides. "Is Bivalirudin Legit? Evidence Grade and Plain-English Verdict." Last reviewed 2026-08-27. https://examinepeptides.com/answers/is-bivalirudin-legit/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.